NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000000713

Registered date:09/05/2007

Efficacy of PEG-IFN alfa-2b plus Ribabirin and HMG-CoA reductase inhibitor combination antiviral therapy ; pilot study

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedChronic hepatitis C
Date of first enrollment2006/12/01
Target sample size10
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)HMG-CoA reductase inhibitor

Outcome(s)

Primary Outcomevirologic response
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximumNot applicable
GenderMale and Female
Include criteria
Exclude criteria1) Patients receiving shosaiko-to 2) Autoimmune hepatitis 3) History of hypersensitivity to PEG-IFN alpha-2b or other interferons 4) History of hypersensitivity to biological products such as vaccine 5) Decompenstated liver cirrhosis 6) HCC, malignat tumor 7) With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 8) Pregnant or lactating women and women who may be pregnant 9) Judged by investigator not to be appropriate for inclusion in this study

Related Information

Contact

public contact
Name Tomokazu Kawaoka
Address 1-2-3 kasumi, minami-ku, Hiroshima Japan
Telephone
E-mail
Affiliation graduate school of biomedical science, Hiroshima university Department and medicine and molecular science
scientific contact
Name Kazuaki Chayama
Address 1-2-3 kasumi, minami-ku, Hiroshima 734-8551 Japan
Telephone
E-mail
Affiliation graduate school of biomedical science, Hiroshima university. Department and medicine and molecular science